Kite Pharma Details CAR-T Therapy Launch, Floats Pricing Benchmarks
Kite plans to initially target 72 clinical institutions experienced with CAR-T for its KTE-C19 launch, including 10 from the get-go.
You may also be interested in...
Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.
Emerging Company Profile: San Francisco startup aligned with Kite Pharma believes T-cells may be programmed to reversibly activate and deactivate, greatly improving specificity, efficacy and safety of chimeric antigen receptor T-cell therapies.
Kite Pharma Inc. executives reiterated plans on Sept. 26 to pursue US FDA approval this year for the chimeric antigen receptor T cell (CAR-T) therapy known as KTE-C19, keeping the company on track to seek accelerated approval for a form of advanced lymphoma before any of its competitors.